Literature DB >> 26081074

Downregulation of the expression of HDGF attenuates malignant biological behaviors of hilar cholangiocarcinoma cells.

Yanfeng Liu1, Jingxian Sun2, Guangyun Yang3, Zhaojian Liu4, Sen Guo1, Rui Zhao1, Kesen Xu1, Xiaopeng Wu1, Zhaoyang Zhang5.   

Abstract

Hepatoma-derived growth factor (HDGF) has been reported to be a potential predictive and prognostic marker for several types of cancer and important in malignant biological behaviors. However, its role in human hilar cholangiocarcinoma remains to be elucidated. Our previous study demonstrated that high expression levels of HDGF in hilar cholangiocarcinoma tissues correlates with tumor progression and patient outcome. The present study aimed to elucidate the detailed functions of the HDGF protein. This was performed by downregulating the protein expression of HDGF in the FRH0201 hilar cholangiocarcinoma cell line by RNA interference (RNAi) in vitro, and revealed that downregulation of the HDGF protein significantly inhibited the malignant biological behavior of the FRH0201 cells. In addition, further investigation revealed that downregulation of the protein expression of HDGF significantly decreased the secretion of vascular endothelial growth factor, which may be the mechanism partially responsible for the inhibition of malignant biological behaviors. These findings demonstrated that HDGF is important in promoting malignant biological behaviors, including proliferation, migration and invasion of hilar cholangiocarcinoma FRH0201 cells. Inhibition of the expression of HDGF downregulated the malignant biological behaviors, suggesting that downregulation of the protein expression of HDGF by RNAi may be a novel therapeutic approach to inhibit the progression of hilar cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26081074     DOI: 10.3892/mmr.2015.3922

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

1.  HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma.

Authors:  Honghong Jiang; Qiaofen Fu; Xin Song; Chunlei Ge; Ruilei Li; Zhen Li; Baozhen Zeng; Chunyan Li; Ying Wang; Yuanbo Xue; Rongcheng Luo; Weiyi Fang
Journal:  Oncol Lett       Date:  2019-09-05       Impact factor: 2.967

2.  Unraveling molecular effects of ADAR1 overexpression in HEK293T cells by label-free quantitative proteomics.

Authors:  Jisheng Guo; Xiaoyue Wang; Xin Lü; Ruirui Jing; Junqiang Li; CuiLing Li; Daoguang Wang; Baibin Bi; Xinjun Chen; Fengqin Wang; Shengnan Sun; Jing Gong; Kazem M Azadzoi; Jing-Hua Yang
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.